Castle Biosciences Inc (CSTL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.01B
Last updated: Nov 17, 2026 at 4:15 PM ET
Castle Biosciences Inc (CSTL) Statistics
Castle Biosciences (CSTL) has a market cap of $1.01B and an enterprise value of $941.39M. Its share count is up 5.37% from a year earlier.
Total Valuation
Enterprise value is 6.73% below the market cap, as cash exceeds debt.
| Market Cap | $1.01B |
|---|---|
| Enterprise Value | $941.39M |
| Latest price (Nov 17, 2026) | $32.98 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.7x and 2.1x. Its year-end P/S ranged from 2.3x to 20.7x from 2019 to 2025.
| P/S Ratio | 2.7x |
|---|---|
| Forward P/S | 2.6x |
| P/B Ratio | 2.1x |
| P/TBV Ratio | 2.6x |
| P/FCF Ratio | 254.9x |
| P/OCF Ratio | 25.4x |
Enterprise Valuation
Counting debt and cash, the company is valued at 237.8x free cash flow.
| EV / Sales | 2.5x |
|---|---|
| EV / FCF | 237.8x |
Price Statistics
The stock is down 1.41% over 52 weeks and trades 3.99% below its 50-day average.
| Beta (1Y) | 1.12 |
|---|---|
| 52-Week Change | -1.41% |
| 1-Month Change | +2.53% |
| 3-Month Change | +2.04% |
| 6-Month Change | +71.77% |
| 5-Year Change | -40.40% |
| Total Return (1Y) | -1.41% |
| Total Return (3Y CAGR) | +18.86% |
| Total Return (5Y CAGR) | -7.73% |
| Return vs SPY (1Y) | -13.26% |
| Max Drawdown (1Y) | -57.83% |
| Max Drawdown (3Y) | -57.83% |
| Sharpe Ratio (1Y) | -0.03 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $34.35 |
| 200-Day Average | $28.12 |
| 52-Week Range | $17.72 to $44.28 |
| RSI (14 Days) | 45.1 |
| Average Volume (20 Days) | 452.70K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.28x current liabilities, and total debt is 0.02x shareholder equity.
| Current Ratio | 5.28x |
|---|---|
| Quick Ratio | 5.12x |
| Debt / Equity | 0.02x |
| Debt / FCF | 2.54x |
| Interest Coverage | 15.03x |
Returns and Efficiency
Return on invested capital is -5.37% over the last 12 months, against a 5-year average of -7.69%.
| Return on Equity (ROE) | -4.81% |
|---|---|
| Return on Assets (ROA) | -3.97% |
| Return on Invested Capital (ROIC) | -5.37% |
| ROE (5Y Average) | -8.05% |
| ROA (5Y Average) | -7.04% |
| ROIC (5Y Average) | -7.69% |
| Asset Turnover | 0.66x |
| Inventory Turnover | 8.25x |
| Receivables Turnover | 7.51x |
| Cash Conversion Cycle | 45 days |
Scores
CSTL has an Altman Z-Score of 6.51, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 6.51 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $377.13M over the last 12 months is up 9.78% from the 12 months before.
| Revenue | $377.13M |
|---|---|
| Revenue Growth (YoY) | +9.78% |
| Gross Profit | $290.66M |
| Operating Income | -$28.04M |
| Pretax Income | -$22.62M |
| Net Income | -$23.01M |
| EBITDA | -$12.17M |
| Reported EPS (TTM) | -$0.77 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 82.57% of the $579.41M in total assets.
| Cash and Equivalents | $77.99M |
|---|---|
| Total Debt | $10.08M |
| Net Cash | $67.91M |
| Net Cash Per Share | $2.22 |
| Working Capital | $289.25M |
| Shareholder Equity | $478.44M |
| Book Value Per Share | $15.62 |
| Tangible Book Value | $386.95M |
| Tangible Book Per Share | $12.63 |
| Total Assets | $579.41M |
| Total Liabilities | $100.96M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $35.78M of capital spending, operating cash flow left $3.96M of free cash flow.
| Operating Cash Flow | $39.74M |
|---|---|
| Capital Expenditures | $35.78M |
| Free Cash Flow | $3.96M |
| FCF Per Share | $0.13 |
| Depreciation and Amortization | $17.85M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -7.43%, against a 5-year average of -27.30%.
| Gross Margin | 77.07% |
|---|---|
| Operating Margin | -7.43% |
| Pretax Margin | -6.00% |
| Net Margin | -6.10% |
| EBITDA Margin | -3.23% |
| FCF Margin | 1.05% |
| Gross Margin (5Y Average) | 80.12% |
| Operating Margin (5Y Average) | -27.30% |
| Net Margin (5Y Average) | -21.98% |
Growth
Revenue grew 35.94% a year over 3 years.
| Revenue Growth (3Y CAGR) | +35.94% |
|---|---|
| Revenue Growth (5Y CAGR) | +40.60% |
| FCF Growth (5Y CAGR) | +40.83% |
| Book Value Per Share Growth (2Y CAGR) | +5.53% |
| Tangible Book Per Share Growth (2Y CAGR) | +11.99% |
Dividends and Yields
CSTL does not pay a dividend. Its free cash flow yield is 0.39%.
| FCF Yield | 0.39% |
|---|---|
| Buyback Yield | -0.36% |
| Shareholder Yield | -0.36% |
Peer Position
Against 10 similar companies, CSTL has the 6th highest P/S.
P/S RatioPeer median 2.9x
ROICPeer median -12.14%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.98%
| P/S Ratio | 2.7x vs 2.9x median |
|---|---|
| ROIC | -5.37% vs -12.14% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +9.78% vs +13.98% median |
Analyst Forecast
Consensus estimates put revenue growth at 12.29% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +12.29% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CSTL
What is CSTL's market cap?
Castle Biosciences has a market cap of $1.01B. Its enterprise value, which adds debt and subtracts cash, is $941.39M.
How many shares of CSTL are outstanding?
Castle Biosciences has 30.63M shares outstanding. The count is up 5.37% from a year earlier.
Does CSTL pay a dividend?
No. Castle Biosciences does not pay a dividend.
How much debt does CSTL have?
Castle Biosciences has $10.08M of total debt and $77.99M of cash and equivalents, a net cash position of $67.91M.
CSTL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts